145 related articles for article (PubMed ID: 20878650)
1. The positive predictive value of a hyperkalemia diagnosis in automated health care data.
Raebel MA; Smith ML; Saylor G; Wright LA; Cheetham C; Blanchette CM; Xu S
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1204-8. PubMed ID: 20878650
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring.
Raebel MA; Ross C; Xu S; Roblin DW; Cheetham C; Blanchette CM; Saylor G; Smith DH
J Gen Intern Med; 2010 Apr; 25(4):326-33. PubMed ID: 20087674
[TBL] [Abstract][Full Text] [Related]
3. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study.
Adelborg K; Nicolaisen SK; Hasvold P; Palaka E; Pedersen L; Thomsen RW
PLoS One; 2019; 14(6):e0218739. PubMed ID: 31226134
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Surabenjawong U; Thunpiphat N; Chatsiricharoenkul S; Monsomboon A
J Med Assoc Thai; 2013 Aug; 96(8):905-10. PubMed ID: 23991595
[TBL] [Abstract][Full Text] [Related]
5. Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates.
Raebel MA; Ross C; Cheetham C; Petersen H; Saylor G; Smith DH; Wright LA; Roblin DW; Xu S
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):19-25. PubMed ID: 19937982
[TBL] [Abstract][Full Text] [Related]
6. Biochemical monitoring after initiation of aldosterone antagonist therapy in users of renin-angiotensin system blockers: a UK primary care cohort study.
Sinnott SJ; Mansfield KE; Schmidt M; Bhaskaran K; Smeeth L; Nitsch D; Tomlinson LA
BMJ Open; 2017 Nov; 7(11):e018153. PubMed ID: 29150471
[TBL] [Abstract][Full Text] [Related]
7. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
8. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
Parikh RV; Nash DM; Brimble KS; Markle-Reid M; Tan TC; McArthur E; Khoshniat-Rad F; Sood MM; Zheng S; Pravoverov L; Nesrallah GE; Garg AX; Go AS
Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006415. PubMed ID: 32873054
[TBL] [Abstract][Full Text] [Related]
9. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
11. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
12. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
13. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
[TBL] [Abstract][Full Text] [Related]
14. Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients.
Movilli E; Camerini C; Gaggia P; Zubani R; Cancarini G
Am J Nephrol; 2018; 48(2):79-86. PubMed ID: 30071530
[TBL] [Abstract][Full Text] [Related]
15. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
[TBL] [Abstract][Full Text] [Related]
16. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
[TBL] [Abstract][Full Text] [Related]
17. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
18. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
19. Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study.
Thomsen RW; Nicolaisen SK; Hasvold P; Garcia-Sanchez R; Pedersen L; Adelborg K; Egfjord M; Egstrup K; Sørensen HT
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29789332
[TBL] [Abstract][Full Text] [Related]
20. New potassium binders reduce the risk of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors.
Tamargo M; Tamargo J
Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):193-194. PubMed ID: 29982385
[No Abstract] [Full Text] [Related]
[Next] [New Search]